새로 진단된 진행성 난소암 환자에서 Niraparib

González-Martı́n 등(토,)이 이 질문을 연구하였다.

www.synapsesocial.com/papers/69d77af93fae90fd6048f479 — DOI: https://doi.org/10.1056/nejmoa1910962

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer· 2007 · 919 citations
2. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)· 2011 · 9,881 citations
3. Validation of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Symptom Index (FOSI) in a phase II clinical trial of pertuzumab in patients with advanced ovarian cancer· 2007 · 17 citations
4. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)· 2008 · 29,240 citations
5. Interim analysis: The alpha spending function approach· 1994 · 568 citations